{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T19:14:17Z","timestamp":1794338057578,"version":"4.9.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.esmoop.2023.101586","type":"journal-article","created":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T20:41:17Z","timestamp":1687639277000},"page":"101586","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region: a report from the APODDC working group"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6607-1106","authenticated-orcid":false,"given":"H.H.","family":"Loong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6632-0638","authenticated-orcid":false,"given":"T.","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2640-9333","authenticated-orcid":false,"given":"A.","family":"Prawira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7292-1114","authenticated-orcid":false,"given":"A.C.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9124-354X","authenticated-orcid":false,"given":"B.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8262-2441","authenticated-orcid":false,"given":"D.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9087-5262","authenticated-orcid":false,"given":"D.S.P.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9161-4918","authenticated-orcid":false,"given":"F.I.L.","family":"Ting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8320-3166","authenticated-orcid":false,"given":"J.W.","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3238-0119","authenticated-orcid":false,"given":"M.","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9106-2607","authenticated-orcid":false,"given":"M.K.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0634-2541","authenticated-orcid":false,"given":"N.","family":"Prasongsook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5807-8458","authenticated-orcid":false,"given":"T.","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3147-7640","authenticated-orcid":false,"given":"T.","family":"Reungwetwattana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5329-7192","authenticated-orcid":false,"given":"T.J.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8894-1355","authenticated-orcid":false,"given":"V.","family":"Heong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9638-9860","authenticated-orcid":false,"given":"P.J.","family":"Voon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9467-461X","authenticated-orcid":false,"given":"S.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4951-0354","authenticated-orcid":false,"given":"I.B.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8998-5480","authenticated-orcid":false,"given":"S.L.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6514-6786","authenticated-orcid":false,"given":"D.S.W.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmoop.2023.101586_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.esmoop.2023.101586_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1741-7015-12-3","article-title":"Managing the changing burden of cancer in Asia","volume":"12","author":"Sankaranarayanan","year":"2014","journal-title":"BMC Med"},{"key":"10.1016\/j.esmoop.2023.101586_bib3","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1186\/s12885-015-1615-0","article-title":"Relationships between cancer pattern, country income and geographical region in Asia","volume":"15","author":"Ng","year":"2015","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2023.101586_bib4","first-page":"256","article-title":"Cancer biomarker discovery and validation","volume":"4","author":"Goossens","year":"2015","journal-title":"Transl Cancer Res"},{"issue":"6","key":"10.1016\/j.esmoop.2023.101586_bib6","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41571-018-0002-6","article-title":"The emerging clinical relevance of genomics in cancer medicine","volume":"15","author":"Berger","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101586_bib7","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3390\/ijms18020308","article-title":"Next-generation sequencing in oncology: genetic diagnosis, risk prediction and cancer classification","volume":"18","author":"Kamps","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.esmoop.2023.101586_bib8","article-title":"Biomarker testing for advanced lung cancer by next-generation sequencing; a valid method to achieve a comprehensive glimpse at mutational landscape","volume":"40","author":"Mehta","year":"2020","journal-title":"Appl Cancer Res"},{"issue":"4","key":"10.1016\/j.esmoop.2023.101586_bib9","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/ajco.13339","article-title":"Recommendations to improve the clinical adoption of NGS-based cancer diagnostics in Singapore","volume":"16","author":"Tan","year":"2020","journal-title":"Asia Pac J Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2023.101586_bib10","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2023.101586_bib11","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1200\/JCO.21.02767","article-title":"Somatic genomic testing in patients with metastatic or advanced cancer: ASCO provisional clinical opinion","volume":"40","author":"Chakravarty","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2023.101586_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000483","article-title":"Cancer medicines in Asia and Asia-Pacific: what is available, and is it effective enough?","volume":"4","author":"Eniu","year":"2019","journal-title":"ESMO Open"},{"issue":"20","key":"10.1016\/j.esmoop.2023.101586_bib13","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.esmoop.2023.101586_bib14","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.esmoop.2023.101586_bib15","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.esmoop.2023.101586_bib16","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101586_bib17","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13058-021-01462-3","article-title":"ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer","volume":"23","author":"Brett","year":"2021","journal-title":"Breast Cancer Res"},{"issue":"8","key":"10.1016\/j.esmoop.2023.101586_bib18","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1093\/annonc\/mdv217","article-title":"Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer","volume":"26","author":"Bidard","year":"2015","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1016\/j.esmoop.2023.101586_bib19","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1200\/JCO.20.02923","article-title":"Pembrolizumab in patients with metastatic breast cancer with high tumor mutational burden: results from the targeted agent and profiling utilization registry (TAPUR) study","volume":"39","author":"Alva","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101586_bib20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"issue":"9742","key":"10.1016\/j.esmoop.2023.101586_bib21","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"issue":"10294","key":"10.1016\/j.esmoop.2023.101586_bib22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"issue":"6349","key":"10.1016\/j.esmoop.2023.101586_bib23","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101586_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"25","key":"10.1016\/j.esmoop.2023.101586_bib25","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.esmoop.2023.101586_bib26","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2023.101586_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.665652","article-title":"Dural and multiple brain metastases from basaloid nasopharyngeal carcinoma: case report and literature review","volume":"11","author":"Geng","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.esmoop.2023.101586_bib29","article-title":"Exome and genome sequencing of nasopharynx cancer identifies NF-\u03baB pathway activating mutations","volume":"8","author":"Li","year":"2017","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.esmoop.2023.101586_bib30","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/ng.3006","article-title":"The genomic landscape of nasopharyngeal carcinoma","volume":"46","author":"Lin","year":"2014","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.esmoop.2023.101586_bib31","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s41591-021-01444-0","article-title":"Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial","volume":"27","author":"Mai","year":"2021","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.esmoop.2023.101586_bib32","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","article-title":"Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial","volume":"22","author":"Yang","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101586_bib33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","article-title":"Epidemiology of ovarian cancer: a review","volume":"14","author":"Reid","year":"2017","journal-title":"Cancer Biol Med"},{"issue":"25","key":"10.1016\/j.esmoop.2023.101586_bib34","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.esmoop.2023.101586_bib35","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.esmoop.2023.101586_bib36","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.esmoop.2023.101586_bib37","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/ijc.25835","article-title":"Frequency of mismatch repair deficiency in ovarian cancer: a systematic review. This article is a US Government work and, as such, is in the public domain of the United States of America","volume":"129","author":"Murphy","year":"2011","journal-title":"Int J Cancer"},{"issue":"21","key":"10.1016\/j.esmoop.2023.101586_bib38","doi-asserted-by":"crossref","first-page":"6847","DOI":"10.1158\/1078-0432.CCR-08-1387","article-title":"Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology","volume":"14","author":"Pal","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101586_bib39","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1277308","article-title":"Clear cell ovarian cancers with microsatellite instability: a unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1\/PD-L1 expression","volume":"6","author":"Howitt","year":"2017","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101586_bib40","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ajur.2014.08.007","article-title":"Chinese Prostate Cancer Consortium, et\u00a0al. Prostate cancer in Asia: a collaborative report","volume":"1","author":"Chen","year":"2014","journal-title":"Asian J Urol"},{"key":"10.1016\/j.esmoop.2023.101586_bib41","doi-asserted-by":"crossref","first-page":"S1105","DOI":"10.1016\/j.annonc.2020.08.1356","article-title":"Genomic characteristics of homologous recombination in prostate cancer patients","volume":"31","author":"Qu","year":"2020","journal-title":"Ann Oncol"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2023.101586_bib42","article-title":"The prevalence of BRCA1\/2 germline mutation in Chinese pan-cancer","volume":"38","author":"Ma","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101586_bib43","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A\u00a0prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Shi","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2023.101586_bib44","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.3892\/ol.2017.5980","article-title":"Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations","volume":"13","author":"Krawczyk","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1016\/j.esmoop.2023.101586_bib45","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.semcancer.2019.09.015","article-title":"Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer","volume":"61","author":"Harrison","year":"2020","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"10.1016\/j.esmoop.2023.101586_bib46","article-title":"Clinical and economic impact of upfront next-generation sequencing for metastatic NSCLC in East Asia","volume":"3","author":"Loong","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.esmoop.2023.101586_bib47","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.lungcan.2019.11.022","article-title":"Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: incremental yield of actionable alterations and cost-effectiveness analysis","volume":"139","author":"Tan","year":"2020","journal-title":"Lung Cancer"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2023.101586_bib48","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/liv.14095","article-title":"Cholangiocarcinoma: epidemiology and risk factors","volume":"39","author":"Khan","year":"2019","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.esmoop.2023.101586_bib49","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/MOG.0b013e3282fbf9b3","article-title":"Cholangiocarcinoma: lessons from Thailand","volume":"24","author":"Sripa","year":"2008","journal-title":"Curr Opin Gastroenterol"},{"issue":"6","key":"10.1016\/j.esmoop.2023.101586_bib50","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2023.101586_bib51","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2023.101586_bib52","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study","volume":"6","author":"Javle","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"suppl 3","key":"10.1016\/j.esmoop.2023.101586_bib53","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.annonc.2020.04.056","article-title":"Efficacy and safety of entrectinib in NTRK fusion-positive gastrointestinal cancers: updated integrated analysis of three clinical trials (STARTRK-2, STARTRK-1 and ALKA-372-001)","volume":"31","author":"Patel","year":"2020","journal-title":"Ann Oncol"},{"issue":"18","key":"10.1016\/j.esmoop.2023.101586_bib54","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.2169\/internalmedicine.4588-20","article-title":"Microsatellite instability-high intrahepatic cholangiocarcinoma with portal vein tumor thrombosis successfully treated with pembrolizumab","volume":"59","author":"Naganuma","year":"2020","journal-title":"Intern Med"},{"issue":"7","key":"10.1016\/j.esmoop.2023.101586_bib55","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S2468-1253(22)00044-9","article-title":"GBD 2019 Colorectal Cancer Collaborators. Global, regional, and national burden of colorectal cancer and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"7","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101586_bib56","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/annonc\/mdu378","article-title":"Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials","volume":"26","author":"Sorich","year":"2015","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.esmoop.2023.101586_bib57","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.esmoop.2023.101586_bib58","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1200\/JCO.2016.71.4394","article-title":"Non-V600 BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer","volume":"35","author":"Jones","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2023.101586_bib59","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2023.101586_bib60","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(18)30904-5","article-title":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study","volume":"20","author":"Meric-Bernstam","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2023.101586_bib61","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial","volume":"17","author":"Sartore-Bianchi","year":"2016","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2023.101586_bib62","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.5858\/arpa.2021-0632-CP","article-title":"Mismatch repair and microsatellite instability testing for immune checkpoint inhibitor therapy: guideline from the College of American Pathologists in Collaboration with the Association for Molecular Pathology and Fight Colorectal Cancer","volume":"146","author":"Bartley","year":"2022","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.esmoop.2023.101586_bib63","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1200\/JCO.22.02462","article-title":"Mismatch repair and microsatellite instability testing for immune checkpoint inhibitor therapy: ASCO Endorsement of College of American Pathologists Guideline","volume":"41","author":"Vikas","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2023.101586_bib64","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jhep.2016.05.035","article-title":"Genetic profiling of hepatocellular carcinoma using next-generation sequencing","volume":"65","author":"Schulze","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"7","key":"10.1016\/j.esmoop.2023.101586_bib65","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1158\/1078-0432.CCR-18-2293","article-title":"Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies","volume":"25","author":"Harding","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.esmoop.2023.101586_bib66","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1158\/1535-7163.MCT-14-0768","article-title":"Loss of tuberous sclerosis complex 2 (TSC2) is frequent in hepatocellular carcinoma and predicts response to mTORC1 inhibitor everolimus","volume":"14","author":"Huynh","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"10.1016\/j.esmoop.2023.101586_bib67","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1172\/JCI27236","article-title":"Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype","volume":"116","author":"Kaposi-Novak","year":"2006","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101586_bib68","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/gutjnl-2021-325918","article-title":"Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification","volume":"72","author":"Montironi","year":"2023","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.esmoop.2023.101586_bib69","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/s41416-021-01535-2","article-title":"Biopsy for advanced hepatocellular carcinoma: results of a multicentre UK audit","volume":"125","author":"Childs","year":"2021","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.esmoop.2023.101586_bib70","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/jgh.15889","article-title":"Personalized treatment for hepatocellular carcinoma: current status and future perspectives","volume":"37","author":"Chan","year":"2022","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"44","key":"10.1016\/j.esmoop.2023.101586_bib71","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2209852119","article-title":"Epigenetic analysis of cell-free DNA by fragmentomic profiling","volume":"119","author":"Zhou","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"40","key":"10.1016\/j.esmoop.2023.101586_bib72","doi-asserted-by":"crossref","first-page":"E5503","DOI":"10.1073\/pnas.1508736112","article-title":"Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments","volume":"112","author":"Sun","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.esmoop.2023.101586_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100487","article-title":"When should we order a next generation sequencing test in a patient with cancer?","volume":"25","author":"Colomer","year":"2020","journal-title":"EClinicalMedicine"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923008207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923008207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:29:42Z","timestamp":1761856182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702923008207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":71,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S2059702923008207"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.101586","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region: a report from the APODDC working group","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.101586","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101586"}}